Carboplatin and paclitaxel in metastatic or recurrent cervical cancer.
Τίτλος | Carboplatin and paclitaxel in metastatic or recurrent cervical cancer. |
Publication Type | Journal Article |
Year of Publication | 2009 |
Authors | Pectasides, D., Fountzilas G., Papaxoinis G., Pectasides E., Xiros N., Sykiotis C., Koumarianou A., Psyrri A., Panayiotides J., & Economopoulos T. |
Journal | Int J Gynecol Cancer |
Volume | 19 |
Issue | 4 |
Pagination | 777-81 |
Date Published | 2009 May |
ISSN | 1525-1438 |
Λέξεις κλειδιά | Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Carcinoma, Squamous Cell, Disease-Free Survival, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Paclitaxel, Retrospective Studies, Uterine Cervical Neoplasms |
Abstract | OBJECTIVES: The purpose of this study was to evaluate the activity and toxicity of carboplatin and paclitaxel combination in advanced or recurrent carcinoma of the cervix.METHODS: Fifty-one eligible patients with measurable advanced or recurrent cervical carcinoma were treated with carboplatin (area under the curve, 5) and paclitaxel 175 mg/m every 3 weeks for 6 to 9 cycles or until disease progression or unacceptable toxicity.RESULTS: Eight complete (16%) and 19 partial responses (37%) occurred, for an overall response rate (RR) of 53% (95% confidence interval [CI], 39%-67%). The median progression-free survival was 6 months (95% CI, 5.4-6.5 months), and the median overall survival was 13 months (95% CI, 11.4-14.5 months). The RR was higher in patients with disease outside a previously irradiated site compared with those with disease in a previously irradiated field (68% vs 30%) (P = 0.011). Patients previously treated with chemoradiation had an RR of 28%, whereas in those previously treated with radiotherapy alone, the RR was 68% (P = 0.023). There was no statistically significant difference between histology and response to therapy. Patients with performance status of 0 or 1 had a higher RR than those with worse performance status. Toxicity was generally mild except for myelotoxicity. Neutropenia grade 3/4 was recorded in 44% of patients, and 6% experienced febrile neutropenia. Twenty-two percent of patients experienced anemia grade 3-4, whereas 14% had thrombocytopenia grade 3-4. Three patients (6%) developed grade 3 sensory neuropathy.CONCLUSION: The combination of carboplatin and paclitaxel seems to have activity in advanced or recurrent cervical carcinoma with an acceptable toxicity profile. |
DOI | 10.1111/IGC.0b013e3181a40a8b |
Alternate Journal | Int. J. Gynecol. Cancer |
PubMed ID | 19509587 |